Private equity major BC Partners has scored what is believed to be a 4x return through the €1.6bn sale of European generic drugmaker Pharmathen to Partners Group.
The post BC Partners believed to score 4x return through €1.6bn Pharmathen sale to Partners Group first appeared on AltAssets Private Equity News.
